Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ETON | PRESS-RELEASE | bullish | 5/10 | Eton Pharmaceuticals submitted a Prior Approval Supplement (PAS) to the FDA seeking to expand KHINDIVI (hydrocortisone) | Jul 29, 2026 |
| ARTV | INSIDER-BUY | bullish | 6/10 | RA Capital Management, a 10% owner and director, made a series of open-market purchases totaling ~$3.07M over 7 days (Ju | Jul 29, 2026 |
| ABBV | COURT-RULING | bullish | 6/10 | The District of North Dakota denied North Dakota's motion to stay a permanent injunction pending appeal, keeping AbbVie' | Jul 29, 2026 |
| SCTX | CLUSTER | bullish | 8/10 | Director and 10% owner Behzad Aghazadeh purchased $35M of SCTX stock at $15/share, alongside smaller open-market buys by | Jul 28, 2026 |
| MPLT | INSIDER-BUY | neutral | 3/10 | Director Troy Cox made a single open-market purchase of 15,620 MPLT shares for ~$149K at $9.52, representing 0.03% of th | Jul 28, 2026 |
| ALNY | INST-CLUSTER | bullish | 4/10 | Four institutional asset managers increased their ALNY positions in Q2 2026, led by Robeco Institutional Asset Managemen | Jul 28, 2026 |
| FTH | 3 | neutral | 5/10 | No summary provided | Jul 28, 2026 |
| PAHC | 8-K | neutral | 2/10 | Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common | Jul 28, 2026 |
| FF | 8-K | neutral | 2/10 | FutureFuel Corp. filed an 8-K solely to announce the date of its Q2 2026 earnings release and conference call. Results w | Jul 28, 2026 |
| LKFT | 6-K | neutral | 2/10 | Lakefront Biotherapeutics disclosed the repurchase of 95,670 shares for ~€2.43M under its existing buyback program, a ro | Jul 28, 2026 |
| TPST | DEFA14A | neutral | 5/10 | Tempest Therapeutics adjourned its special meeting of stockholders on July 27, 2026, due to insufficient votes to approv | Jul 28, 2026 |
| OPTH | 6-K | neutral | 3/10 | Optimi Health Corp. filed its annual meeting proxy materials, including a management information circular and forms of p | Jul 28, 2026 |
| NKTR | PRESS-RELEASE | neutral | 1/10 | Nektar Therapeutics announced it will report its Q2 results on August 13, 2026. | Jul 28, 2026 |
| MEOH | PRESS-RELEASE | bearish | 6/10 | Methanex reported Q2 2026 Adjusted net income per share of $3.87, below the $4.01 consensus estimate, a miss of -3.5%. R | Jul 28, 2026 |
| GSK | 6-K | neutral | 4/10 | GSK announced plans to build a new flagship R&D centre on the Cambridge Biomedical Campus in the UK, with a £400 million | Jul 28, 2026 |
| GSK | 6-K | bullish | 6/10 | GSK's licensor Hansoh Pharma announced positive Phase III results for risvutatug rezetecan (Ris-Rez) in relapsed osteosa | Jul 28, 2026 |
| GSK | 6-K | mixed | 6/10 | GSK reported Q2 2026 core results with total sales of £8.4 billion (+5% CER) and core EPS of 50.5p (+9% CER), driven by | Jul 28, 2026 |
| RADX | 6-K | bearish | 6/10 | Radiopharm Theranostics filed a 6-K on July 28, 2026, confirming the closing of its previously announced US$4.1 million | Jul 28, 2026 |
| OKYO | 6-K | neutral | 3/10 | OKYO Pharma's Chief Scientific Officer Raj Patil purchased 3,363 ordinary shares at $1.49 per share on the open market, | Jul 28, 2026 |
| IQV | 8-K | bullish | 7/10 | IQVIA reported Q2 2026 results that beat consensus on both revenue and adjusted EPS, with revenue of $4,368M (+8.7% YoY) | Jul 28, 2026 |
| INCY | 8-K | mixed | 6/10 | Incyte reported Q2 2026 GAAP diluted EPS of $2.81 (vs consensus $2.15, +30.7% beat) and total revenue of $1.67B (vs cons | Jul 28, 2026 |
| ALT | 8-K | bullish | 7/10 | Altimmune announced positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) | Jul 28, 2026 |
| RDHL | 6-K | neutral | 5/10 | RedHill Biopharma provided an update on its opaganib development for Ebola virus disease (EVD) as the Bundibugyo ebolavi | Jul 28, 2026 |
| ALKS | 8-K | bearish | 6/10 | Alkermes reported Q2 2026 revenue of $496.0M (+27% YoY), driven by the Avadel acquisition adding LUMRYZ ($96.6M). GAAP n | Jul 28, 2026 |
| GRCE | 8-K | neutral | 5/10 | Grace Therapeutics announced receipt of FDA Type A meeting minutes regarding the Complete Response Letter (CRL) for its | Jul 28, 2026 |
| GLMD | 6-K | neutral | 4/10 | Galmed Pharmaceuticals announced preclinical progress on an orally dispersible film (ODF) formulation of its SCD1 inhibi | Jul 28, 2026 |
| KZIA | 6-K | bullish | 7/10 | Kazia Therapeutics filed a provisional patent for a novel perioperative strategy using paxalisib to prevent metastatic r | Jul 28, 2026 |
| RADX | 6-K | bearish | 6/10 | Radiopharm Theranostics filed a 6-K with the ASX to quote 384,493,800 new ordinary shares issued at AUD 0.015 per share, | Jul 28, 2026 |
| VXRT | 8-K | neutral | 2/10 | Vaxart filed an 8-K reporting a routine reorganization of its Board committees, appointing Kevin P. Finney as chair of t | Jul 28, 2026 |
| ENLV | 6-K | bearish | 8/10 | Enlivex announced a $400M private placement of ordinary shares at a premium to market price, with proceeds intended to f | Jul 28, 2026 |